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Immunohistochemical staining for FHIT and PCNA proteins was carried out in 451 breast lesions showing nonproliferative benign
breast disease (BBD) (n¼263), proliferative BBD without atypia (n¼128), proliferative BBD with atypia (n¼11), carcinoma in situ
(n¼15) or invasive carcinoma (n¼34) and for EGFR protein in a subset of 71 of these cases. FHIT underexpression was not
detected in nonproliferative lesions, but occurred in 2% of proliferative BBD without atypia, 10% proliferative BBD with atypia, 27% of
carcinoma in situ and 41% of invasive carcinoma, which suggests that it could be useful in assessing those carcinoma in situ lesions
(ductal, DCIS and lobular, LCIS) that are more likely to progress to malignancy. Preliminary microarray comparisons on DCIS and
invasive carcinoma samples dissected from formalin-fixed paraffin sections showed a consistent downregulation of two previously
identified FHIT-related genes, caspase 1 and BRCA1 in lesions underexpressing FHIT.
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Benign breast disease (BBD) and carcinoma in situ (ductal, DCIS
and lobular, LCIS) represent a group of histologically hetero-
geneous lesions, some of which are associated with increased risk
for invasive breast cancer. In moderate to florid usual type ductal
hyperplasia (UDH) and in papillomas, the relative risk (RR) of
developing invasive breast cancer is small (RR¼1.5–2.0), but this
rises in atypical ductal hyperplasia (ADH, RR¼4.0–5.0) (Page and
Dupont, 1989) and in carcinoma in situ (DCIS or LCIS, RR¼8.0–
10.0) (Page, 1991; Page et al, 2000). Pathological and clinical
evidence suggests that different BBD lesions have different
magnitudes of risk for the subsequent development of malignancy
and one of the key challenges is to identify at an early stage those
BBD lesions which could progress to cancer. Certain pathologies
have been associated with higher risk of malignancy, for example
atypical ductal hyperplasia (ADH) and LCIS, but their diagnosis is
subject to considerable interobserver variability (Elston et al, 2000)
and therefore any independent molecular attribute could help
in improving consistency as well as providing insight into the
underlying biology.
Underexpression of the FHIT gene has frequently been linked to
human cancer including breast cancer (Pekarsky et al, 2002). The
FHIT gene is located at chromosome 3p14.2. It spans 1.8 Mb and
has 10exons. Exons 5–9 code for a small mRNA of 1.1kb, which is
susceptible to modification by alternative splicing and down-
regulation by promoter methylation. The FHIT protein (16.8kDa)
is mainly localised in the cytoplasm of epithelial cells complexed
with tubulin and a ubiquitin conjugating enzyme, UBC9 (Shi et al,
2000; Golebiowski et al, 2004). Experimental results have shown
that FHIT protein functions as a hydrolase for intracellular
diadenosine triphosphate that is involved in the control of cell
growth. It is associated with check point proteins ATR and CHK1
(Hu et al, 2005) and is a target for Src protein kinase, suggesting
that FHIT protein is also involved more directly in the cell cycle
(Pekarsky et al, 2004). In addition, FHIT is known to be a
proapoptotic protein closely associated with FADD, caspase-8
(Dumon et al, 2001; Ishii et al, 2001; Roz et al, 2002, 2004), MDM2
and p53 (Nishizaki et al, 2004).
In the breast, loss of heterozygosity (LOH) at the FHIT locus
has been observed in 45% of invasive cancers (Ca) and in 11% of
unspecified preneoplastic lesions including usual type ductal
hyperplasia (UDH), aprocrine metaplasia, DCIS and intraductal
papilloma (Maitra et al, 2001). In another study, reduction or loss
of FHIT protein expression was found in 40–80% of Ca and in 60%
of CIS (Gatalica et al, 2000; Yang et al, 2001). Univariate analysis of
disease-free survival showed FHIT to be a significant prognostic
factor in patients with early breast cancer (Yang et al, 2001;
Ginestier et al, 2003). Although the frequency of abnormalities in
the FHIT gene is comparable to, if not in excess of those found for
currently used biomarkers for breast cancer such as p53 or HER2
(Stark et al, 2000; Arun et al, 2005), the potential role for FHIT
in predicting malignant progression in BBD has not been fully
assessed. We report here the expression of FHIT and PCNA
proteins in 451 cases with benign or malignant breast disease and
EGFR in a subset of 71 of these cases. Our results show that
underexpression of FHIT may have some use as a marker of breast
disease progression in BBD. As the incidence of FHIT under-
expression increases at the stage of carcinoma in situ, we have
undertaken a preliminary examination of the cell environment
associated with normal and abnormal FHIT expression in DCIS
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sand invasive carcinoma using expression microarrays to evaluate
the possible function of this protein in breast tissues. The use of
FHIT protein detection for the monitoring of breast disease
progression is discussed.
MATERIALS AND METHODS
Formalin-fixed and paraffin-embedded (FFPE) sections
were obtained from 787 archival blocks from 532 women.
Biopsies from 451 women were tested and reported in this
study, made up of the following groups: nonproliferative BBD
(n¼263), proliferative BBD without atypia (n¼128), proliferative
BBD with atypia (n¼11), carcinoma in situ (n¼15) and invasive
carcinoma (n¼34). Biopsies from 10 women with incomplete
histology data and from 71 women whose tissue sections were
damaged during staining were excluded from the study. The
routine and reviewed histology results were combined. To classify
the biopsy and select a lesion from several co-existing lesions,
preference was given to lesion categories in the order of severity:
Invasive carcinoma 4carcinoma in situ 4proliferative lesions
with atypia 4proliferative lesions without atypia 4nonprolifera-
tive lesions (Page et al, 2000). Among coexisting lesions within the
same category, preference was given in the order of : extent
4severity.
Sections for immunohistochemical staining (IHS) were 3mm
thick and were stored at 41C. Sections for microarray analysis were
10mm thick and stored at  801C. Ethics approval was obtained
from Guy’s Hospital NHS Trust Ethics Committee for the use of
this archival material.
Immunohistochemical staining
All sections were de-waxed, processed for epitope retrieval and
stained as previously described (Terry et al, 2004). Rabbit anti-
FHIT antibody (Zymed Laboratories Inc., California, USA) and
horse-radish peroxidase (HRP)-conjugated anti-rabbit antibody
(Abcam Ltd, Cambridgeshire, UK) were used for detection of FHIT
protein. Mouse anti-PCNA antibody (Sigma-Aldrid Ltd, Dorset,
UK) and alkaline phosphatase (ALP)-conjugated goat anti-mouse
(Abcam) were used for PCNA protein. FHIT and PCNA proteins
were stained simultaneously. Mouse anti-EGFR antibody (Abcam)
and HRP-conjugated anti-mouse antibody (Abcam) were used for
the detection of EGFR protein, with haematoxylin as counter-stain.
HRP and ALP were detected using the corresponding detection
kits (Abcam).
The results were scored ‘blind’ and independently by three
laboratory scientists. A lesion was scored positive if the stained
section from any of the associated paraffin blocks was scored
positive by two or more observers. The scoring system used for
each protein was as follows:
(a) FHIT. Cytoplasmic staining was graded as normal (2)o r
underexpressed (k). Underexpression was assigned if 430%
of cells in the designated histological category showed absent
or reduced staining when compared to adjacent normal breast
tissue.
(b) PCNA. Nuclear staining of 500 nuclei in the designated
histological category were counted. Overexpression (m) was
assigned if 410% of the nuclei showed either (i) red
trabeculated, (ii) intensely red or (iii) cloudy red stain.
Otherwise, the lesion was scored as normal (2).
(c) EGFR. Membrane staining for EGFR. Overexpression (m) was
assigned if complete membrane staining was present in the
designated histological category. Sections obtained from
lesions, which showed EGFR gene amplification, was used as
control. Lesions with no staining were scored as normal (2).
Of the 79 stained lesions, eight (two with FHIT under-
expression and six with normal FHIT expression) showed
either cytoplasmic staining only or cytoplasmic and mem-
brane staining combined and were excluded from the analysis.
Intense cytoplasmic stain in some cells can lead to a false
impression of a positively stained membrane.
EGFR gene amplification analysis by polymerase chain
reaction
DNA extracts from 14 available paraffin sections were analysed.
Quantitation of polymerase chain reaction (PCR) fragments was
carried out by AlfExpress as previously described (Terry et al,
2004). The primers used were as follows:
(a) EGFR exon 8 forward 50-CGCAAGTGTAAGAAGTGCGAA-30,
reverse 50-CGTAGCATTTATGGAGAGTGAGTCT-30.
(b) GAPDH exon 9 forward 50-CCCCCACCACACTGAATCT-30,
reverse 50-CTAGGCCCCTCCCCTCTT-30.
Microarray analysis using human cancer arrays (MWG
Biotech, Ebensberg, Germany)
(a) RNA extraction and amplification (1.5 cycles) from paraffin-
embedded sections were carried out using the Paradise
Reagent System from Arcturus Bioscience Inc., California,
USA, in accordance with the manufacturer’s instruction.
(b) Incorporation of Cy3- or Cy5-UTP (Perkin-Elmer Life and
Analytical Sciences) was carried out during the IVT stage of
the final amplification half-cycle using MEGAscript reagents
(Ambion Inc., Cambridgeshire, UK) in accordance with the
manufacturer’s instructions and the amplified RNA (aRNA)
purified using Arcturus Paradise kit reagents.
(c) aRNA analysis. aRNA was quantitated spectroscopically using
an ND-1000 spectrophotometer (NanoDrop Technologies,
Delaware, USA) and its size measured by electrophoresis in
formaldehyde-containing agarose gels (Maniatis et al, 1982).
In total, 15mg each of Cy3- and Cy5-labelled aRNAs were
mixed and used for hybridisation to each array.
(d) Hybridisation to MWG human cancer gene arrays spotted
with 50-mer oligonucleotides specific for 1853 human genes
involved in cancer development was carried out according
to the manufacturer’s protocol (MWG Biotech, Ebersberg,
Germany). Arrays were scanned by MWG Scanning Service
(Ebersberg, Germany) using an Affymetrics 428 scanner. Each
channel (Cy3 or Cy5) was scanned at 10mm resolution at three
different photomultiplier gain settings. Fluorescence intensity
values from each channel were processed using Imagene
4.2 software (Biodiscovery, Inc., California, USA). To obtain
maximal signal intensities without saturation effects, intensity
values from Tiff images were integrated into one value per
probe by the MAVI software (Version Pro 2.6.0, MWG
Biotech, Ebersberg, Germany). A negative control threshold
was calculated from the mean fluorescence intensities
obtained for 28 control Arabidopsis oligonucleotides. Fluo-
rescence intensity values for cellular genes that exceeded this
threshold by two standard deviations were regarded as
significant expression signals.
Analysis of the signals was carried out by MWG Analysis Service
(Ebersberg, Germany). Essentially, signals were calculated as
median intensity minus median background. Sample intensities
were normalised by the 50th percentile (median) method using all
of the spot-filtered genes. Spots flagged bad or not found were
excluded from further analysis.
Analysis of trend and variance was carried out using STATA
Statistics and Data Analysis package v 8.2.
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Staining for FHIT, PCNA and EGFR
Figure 1 shows H&E and dual staining for FHIT and PCNA
proteins of (A) an FHIT-negative cancer, (B) an FHIT-reduced low-
grade DCIS and (C) an FHIT-positive florid hyperplasia. A cancer
stained with H&E and EGFR is shown in (D). Arrows indicate
PCNA-positive trabeculated staining, PCNA-positive intensive
staining and PCNA-positive cloudy staining nuclei.
The expression of FHIT, PCNA and EGFR proteins in
breast lesions
The expression of FHIT and PCNA in all 451 biopsies and EGFR in
a subset of 71 biopsies showing proliferative changes is
summarised in Table 1 and Figure 2. FHIT was expressed normally
in all nonproliferative BBD lesions, but was underexpressed in 12%
of all proliferative lesions particularly in those with atypia and
cancerous changes (w
2
trend¼114.31, P¼o0.0001). In all, 60–100%
of all lesions overexpressed PCNA and 5–53% overexpressed
EGFR in parallel with increasing lesion grades (w
2
trend¼13.02,
P¼0.00031). Only three of the 14 cases overexpressing EGFR
showed EGFR gene amplification relative to the GAPDH house-
keeping gene (Figure 3). All lesions, which underexpressed FHIT,
also overexpressed PCNA (Table 2). Although FHIT underexpres-
sion and EGFR overexpression followed a overall similar distribu-
tion in proliferative BBD lesions and in invasive carcinomas, they
were not always concordant in individual cases. Three DCIS and
seven invasive carcinomas with normal EGFR expression under-
expressed FHIT, whereas two DCIS and 11 invasive carcinomas
with normal FHIT expression overexpressed EGFR (Table 2).
Multivariate analysis showed correlation between the three
markers together and increasing lesion grades (F¼5.582,
P¼0.0017).
Comparison of FHIT-related gene expression in ductal
carcinoma in situ and cancer lesions
RNA extracted from paired FHIT-positive and FHIT-negative
lesions were amplified, labelled separately with either Cy3- or Cy5-
UTP and pooled. The amounts of aRNA recovered after two
amplification cycles was 16–20mg and the predominant size was
300–600 bases, but extending up to 2000 bases (data not shown).
Differentially labelled RNA from three DCIS pairs and one invasive
carcinoma pair were hybridised to separate human cancer gene
arrays.
Figure 4 shows good pair-wise correlation between RNA
extracted from an FHIT-positive DCIS labelled with Cy-3 and an
FHIT-negative DCIS labelled with Cy-5 hybridised to 1853 cancer
gene probes with a correlation coefficient of 0.938. A comparison
of the Cy3/Cy5 ratios showed that two genes, caspase 1 and BRCA1,
were underexpressed in all four lesions with reduced FHIT
expression (Table 3).
DISCUSSION
Oncogenesis represents an interplay between cell proliferation
and apoptosis. Markers for these biological activities have been
extensively sought in breast cancer for prognosis, prediction of
treatment effectiveness and development of new chemotherapeutic
agents. Whether the same markers can be used for predicting risk
of subsequent changes in BBD and precursor progression in DCIS
has not been extensively studied. We have used the cell cycle
protein PCNA and the mitogenic receptor EGFR as markers of
proliferation, and FHIT as a marker associated with apoptosis.
Table 1 and Figure 2 summarise the relationship between the
proliferative activities observed in breast lesions and PCNA, EGFR
or FHIT expression. Of the 451 cases studied, 312 (69%) were




Figure 1 Staining patterns in four breast lesions. Upper row (H&E). Cancer (A and D), DCIS (B) and hyperplasia (C). Lower row (ISH). Cancer (A),
DCIS (B) and hyperplasia (C) dually stained with antibodies to FHIT (brown) and PCNA (red). (D) Cancer stained with antibody to EGFR (brown) and
haematoxylin (blue). Arrows indicate different staining patterns: PCNA (i) trabeculated, (ii) intense, (iii) cloudy, (iv) cloudy and EGFR (v) membrane-
associated.
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sthat reported previously (Steck and El-Naggar 1994; Fabian et al,
2002; Honrado et al, 2005). The synthesis of PCNA is closely
associated with the normal G1/S transition of the cell cycle and the
protein has a comparatively long half-life. It is, therefore, a good
marker for measuring proliferative activity in breast lesions where
cells are at different phases of growth and accounts for its apparent
expression in 94–100% of in situ and invasive carcinomas and
even 61% of histologically ‘nonproliferative’ BBD (Table 1,
Figure 2). In contrast, overexpression of the mitogenic signalling
mediator EGFR, indicative of abnormalities in the commitment of
G1 to S phase in the cell cycle, was found in 30% of breast lesions,
predominantly in invasive carcinoma (53%). Similar rates of EGFR
overexpression have been reported previously in DCIS and
invasive carcinoma (Knoop et al, 2001; Lebeau et al, 2003). The
Table 1 FHIT, PCNA and EGFR proteins in nonproliferative and proliferative breast lesions
Pathology
Relative risk of cancer
(Page et al, 2000) Breast lesions
No. of cases with expression status as
Lesion Category (Stark et al, 2000) FHIT PCNA EGFR
k2 m k m2
BBD (a) Nonproliferative 1.0 Normal 0 60 24 36 ND ND
Inflammation 0 13 6 7 ND ND
Cyst 0 4 3 1 ND ND
Metaplasia 0 18 15 3 ND ND
Blind duct adenosis 0 60 35 25 ND ND
Hyperplasia (usual type) 0 24 17 7 ND ND
Fibroadenoma 0 84 60 24 ND ND
Subtotal 0 (0%) 263 160 (61%) 103 NA NA
(b) Proliferative without atypia 1.5–2.0 Papilloma 0 25 16 9 ND ND
Sclerosing adenosis 0 36 29 7 ND ND
Hyperplasia (moderate) 1 47 35 13 0 4
Hyperplasia (florid) 2 17 16 3 1
a 14
Subtotal 3 (2%) 125 96 (75%) 32 1 (5%) 18
(c) Proliferative with atypia 4.0–5.0 ADH/ALH 1 (10%) 10 9 (82%) 2 1 (17%) 5
Carcinoma (a) In situ 8.0–10.0 LCIS 0 3 12 0 0 3
DCIS 4 8 3 0 2 9
Subtotal 4 (27%) 11 15 (100%) 0 2 (17%) 12
(b) Invasive NA 14 (41%) 20 32 (94%) 2 17
b(53%) 15
22(5%) 429 312 (69%) 139 21 (30%) 50
Total n¼451 n¼451 n¼71
aGene amplification detected in one case; 2¼normal level of expression; m¼overexpression; k¼underexpression; ND¼not done; NA¼not applicable.
bGene
































Figure 2 The detection of FHIT, PCNA and EGFR expression in





















































Figure 3 Quantitation of Cy5-labelled EGFR and GAPDH amplicons (in
arbitrary units) from 14 EGFR-positive lesions by sequencing gel
electrophoresis (AlfExpress) using Fragment Manager v.1.2 software
(Pharmacia). ’, gene amplification.
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scauses of EGFR overexpression are not well understood
but aneusomy of chromosome 7 on which the EGFR gene is
located does not relate directly to EGFR protein overexpression
(Bhargava et al, 2005; Sauer et al, 2005). In our study, gene
amplification could only account for three out of 14 cases (Table 1,
Figure 3), but our method would not distinguish between
aneusomy of chromosome 7 from any other mechanism for gene
amplification.
Overall, our results suggest that most BBD lesions and
carcinomas contain populations of rapidly dividing normal and/
or abnormal cells and both are predisposed to accumulation of
genomic changes. This could include the establishment of FHIT
underexpression in a subset of proliferative BBD lesions and
carcinomas.
FHIT underexpression was found in 14 out of 34 (41%) of
invasive carcinomas and in four out of 12 (33%) of DCIS (Table 1,
Figure 2). Previously, loss of FHIT expression in cancer has been
found to mirror other poor prognosis markers, being positively
correlated with Bcl-2 and p53 overexpression, proliferative activity
and aggressive histological phenotype and negatively correlated
with oestrogen and progesterone receptor status (Campiglio et al,
1999; Yang et al, 2001; Arun et al, 2005). Loss of FHIT expression
has also been found to confer a significant disadvantage in disease-
free survival (Yang et al, 2001; Ginestier et al, 2003). However, the
incidence of FHIT expression in BBD lesions in the absence of
invasive carcinoma was unclear. In a study involving 50 cancers,
Gatalica et al (2000) found reduced FHIT protein expression in
four out of 34 (12%) hyperplastic epithelium (grades not
specified), 26 out of 47 (55%) atypical hyperplasia and DCIS
combined and 33 out of 46 (72%) cancers. In a study of 45 cancers,
LOH at the FHIT locus 3p14.2 was found in five out of 45 (11%) of
cancer-associated pre-neoplasia (grades not specified but included
UDH, apocrine metaplasia, DCIS and intraductal papilloma) and
20 out of 44 (45%) cancers (Maitra et al, 2001). In both studies, the
BBD lesions examined were adjacent to cancer tissues and the
staining characteristics observed may not be a reflection of the true
FHIT status as this could have arisen from a local field effect
(Cavalli et al, 2004). In our study, each of the cases tested was
classified by the highest grade of lesion present. We found normal
expression of FHIT protein in all nonproliferative lesions, but
underexpression in 2% of proliferative lesions without atypia, 10%
of proliferative lesions with atypia, 0% of lobular carcinoma
in situ, 33% of ductal carcinoma in situ and 41% of invasive
carcinomas (Table 1). The outcome was known for eight of the 12
DCIS lesions. Two of three lesions with FHIT underexpression and
five of five lesions with normal FHIT expression progressed
subsequently to invasive breast cancer, but the difference was not
Table 2 Corrleation of FHIT, PCNA and EGFR expression in nonproliferative and proliferative breast lesions
Category Grade
Expression status (no. of cases)
FHIT 22kk FHIT 2k k2
PCNA mk m k
EGFR mm 2 2
BBD (a) Nonproliferative Normal 24 36 0 0 ND ND ND ND
Inflammation 6 7 0 0 ND ND ND ND
Cyst 3 1 0 0 ND ND ND ND
Metaplasia 14 4 0 0 ND ND ND ND
Blind duct adenosis 35 25 0 0 ND ND ND ND
Hyperplasia (usual type) 17 7 0 0 ND ND ND ND
Fibroadenoma 60 24 0 0 ND ND ND ND
(b) Proliferative Papilloma 16 9 0 0 ND ND ND ND
without atypia Sclerosing adenosis 29 7 0 0 ND ND ND ND
Hyperplasia (moderate) 34 13 1 0 0 0 1 3
Hyperplasia (florid) 14 3 2 0 1 0 0 14
(c) Proliferative ADH/ALH 8 2 1 0 0 1 0 5
with atypia
Carcinoma (a) In situ LCIS 3 0 0 0 0 0 0 3
DCIS 8 0 4 0 2 0 3 6
(b) Invasive 18 2 14 0 11 6 7 8
Total 289 140 22 0 14 7 11 39
n¼451 n¼71
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Figure 4 Correlation of Cy3-labelled FHIT-positive DCIS and Cy5-
labelled FHIT reduced DCIS hybridised to MWG human cancer gene array.
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ssignificant (P¼0.375). Similarly, no relationship could be
ascertained between FHIT underexpression and different patholo-
gical types of in situ or invasive carcinoma because of the small
number of lesions analysed.
In vitro experiments have shown that FHIT is a proapoptotic
protein which operates via both the extrinsic (Roz et al, 2004) and
intrinsic pathways (Dumon et al, 2001; Ishii et al, 2001). In a study
involving 100 colorectal adenocarcinomas, Mady and Melhem
(2002) found that overexpression of FHIT is directly proportional
to the rate of apoptosis. It was therefore of interest to assess if
underexpression of FHIT in our biopsies is likely to have any
functional effect. To do this, we used expression microarray
analysis to assess the expression levels of other apoptosis-
associated and breast cancer prognostic genes (Table 3). A
commercially available protocol (Paradise kit, Arcturus, Bio-
sciences Inc., California, USA) was successful in amplifying RNA
retrieved from formalin-fixed and paraffin-embedded breast
lesions. Pair-wise analysis confirmed other reports (Ma et al,
2003; True et al, 2006) that good-quality aRNA could be
reproducibly obtained for hybridisation to microarrays (Figure 4).
This technique is invaluable for analysis of archival material.
Although only three of the four DCIS lesions with underexpressed
FHIT expression (Table 1) were available for testing in this
study, consistent downregulation of two genes, namely caspase 1
and BRCA1, was noted. Caspase 1 is an important regulator of
epithelial cell apoptosis and its downregulation has been reported
in breast, gastric, colon and prostate cancers (Boudreau et al, 1995;
Jarry et al, 1999; Winter et al, 2001; Jee et al, 2005). Loss of BRCA1
is associated with a more aggressive phenotype in sporadic breast
cancer (Jarvis et al, 1998; Taylor et al, 1998) and concomitant loss
of FHIT and BRCA1 alleles has also been reported in a number
of repair-deficient cancers including breast cancer and ovarian
cancers (Wilson et al, 1999; Turner et al, 2002; Santos et al, 2004).
In this study, coexpression of PCNA and FHIT was determined
in the same cell population by dual staining, and EGFR was
monitored in the same cell population in an adjacent section.
This allows a simultaneous assessment of an interplay between the
expression of the three proteins. Our results showed that the





F+/F  F+/F7 F+/F7 F+/F7
Median value for all genes 1.041/0.789 0.753/0.456 1.048/0.690 0.979/0.647
Median ratio for all genes 1.319 1.651 1.519 1.513
FHIT-apoptosis APAF1 0.022 1.228 0.528 0.698
BAD 0.394 1.530 0.737 0.629
BAX 3.481 0.882 1.322 1.078
BCL2 (probe 1) 0.973 0.649 0.744 0.912
BCL2 (probe 2) 0.340 2.053 1.028 0.638
BIRC5 0.296 2.335 1.170 0.453
CASP1 1.666 2.263 8.992 4.758
CASP10 2.089 0.535 0.716 1.273
CASP8 2.998 1.035 0.940 0.939
CDC2 ND ND 1.758 0.337
COX7A2L 2.637 1.989 1.462 1.060
CFLAR 0.627 1.172 0.988 0.903
FADD 0.180 1.900 1.167 0.616
FAS 0.685 1.044 3.079 4.253
FASLG 0.114 0.578 1.213 0.641
IL1B 0.030 0.554 1.058 0.660
IL1RN 0.039 0.732 0.679 1.697
FHIT-cell cycle ATM 0.351 0.772 1.111 0.776
WWOX 3.112 0.902 1.122 1.185
Breast cancer prognostic markers AKT1 1.254 0.734 0.759 0.850
AR 0.310 0.780 1.016 0.646
BRCA1 (probe 1) 0.660 1.527 1.085 1.650
BRCA1 (probe 2) 1.724 14.354 13.737 23.800
BRCA2 1.537 ND 1.267 1.338
EGFR 2.858 0.527 1.318 0.998
ERBB2 1.975 0.751 0.617 0.520
ERBB3 0.683 1.539 0.863 3.632
ERBB4 2.036 0.980 0.808 1.064
ESR1 0.415 6.568 0.970 0.551
MLH1 0.089 0.869 2.323 0.952
MLH3 2.134 0.646 2.710 24.352
PCNA 0.236 0.630 0.801 0.526
PGR 0.991 1.737 20.092 10.050
SRC 0.135 0.710 1.515 0.889
TNF 1.583 0.934 0.684 0.708
TP53 0.933 5.030 0.689 0.607
ND¼instensity in one or both channels below the cutoff levels set by the MAVI software; F+¼normal FHIT expression; F  or F7¼FHIT underexpression.
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spresence of PCNA does not clearly distinguish between non-
proliferative BBD lesions and proliferative BBD lesions (with or
without atypia), or between in situ carcinomas and invasive
carcinomas (Table 1). In contrast, underexpression of FHIT was
associated with lesions with increasing severity (w
2
trend¼114.31),
including four out of 12 DCIS and 14 out of 34 invasive
carcinomas. Three DCIS and seven invasive carcinomas with
normal EGFR expression underexpressed FHIT (Table 2), which
suggest that detection of FHIT expression could be of use either
alone or with other markers such as EGFR, in identifying a subset
of proliferative breast lesions with malignant potential. In contrast
to the current lack of consensus in scoring EGFR expression by
IHS, detection of FHIT is technically simple and the incorporation
of a quantitation step by image analyser would provide an
objective measure of its expression (Mady and Melhem, 2002). The
loss of caspase 1 in DCIS lesions also merits further analysis since
the effectiveness of a number of therapeutic drugs depends on its
activation.
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